Return to overview
References
1. DeFronzo RA. From the triumvirate to the ominous octet:
a new paradigm for the treatment of type 2 diabetes
mellitus.Diabetes. 2009;58(4):773-795.
2. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic
approach to therapy in patients with newly diagnosed
type 2 diabetes. Diabetes Care. 2013;36(suppl 2):
S127-S138.
3. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors
in the brain: controlling food intake and body weight.
J Clin Invest. 2014;124(10):4223–4226.
4. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and
GIP. Gastroenterology. 2007;132(6):2131–2157.
5. Bunck MC, Cornér A, Eliasson B, et al. Effects of
exenatide on measures of ß-cell function after 3
years in metformin-treated patients with type 2
diabetes. Diabetes Care. 2011;34(9):2041-2047.
6. Bunck MC, Diamant M, Cornér A, et al. One-year
treatment with exenatide improves ß-cell function,
compared with insulin glargine, in metformin-treated
type 2 diabetic patients. Diabetes Care. 2009;32(5):
762-768.
7. DeFronzo RA, Davidson JA, Del Prato S. The role of the
kidneys in glucose homeostasis: a new path towards
normalizing glycaemia. Diabetes Obes Metab. 2012;
14(1):5-14.
8. Gibson CD, Carnell S, Ochner CN, Geliebter A.
Neuroimaging, gut peptides and obesity: novel
studies of the neurobiology of appetite.
J Neuroendocrinol. 2010;22(8):833-845.
9. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its
role in type 2 diabetes mellitus. Mol Cell Endocrinol.
2009;297(1-2):127-136.
10. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH.
Abnormal alpha-cell function in diabetes. Response
to carbohydrate and protein ingestion. N Engl J Med.
1970;283(3):109-115.